Bevacizumab CAS NO.216974-75-3

Our company has been in existence for 10 years since its establishment. We have our own unique team. The company  integrates independent research and development, production and sales. We have established famous brands at home and  abroad. At present, our customers have spread all over the world, we have rich Transportation experience, we aim to  serve customers, to help customers, solve problems for customers. Look forward to working with you!

Bevacizumab, a humanized IgG1 monoclonal antibody against vascular endothelial growth factor (VEGF), inhibits tumor angiogenesis and delays disease progression. It was launched in the US as an intravenous infusion for the treatment of metastatic colorectal cancer in combination with fluorouracil-based chemotherapy. Bevacizumab was developed by engineering the VEGF binding residues of the murine neutralizing antibody A.4.6.1 into the framework of the consensus human IgG1. Its amino acid sequence is approximately 93% human IgG and 7% murine antibody and is produced in a CHO cell expression system. Bevacizumab binds VEGF with high affinity (K_d=0.5 nM) and prevents its interaction with tyrosine kinase receptors VEGFR1 and VEGFR2 on the surface of endothelial cells, thereby inhibiting cell proliferation and microvascular growth. In mouse models, administration of bevacizumab blocked the growth of human tumor xenografts and reduced the size and number of metastases. The recommended dosage of bevacizumab is 5 mg/kg administered once every 2 weeks as an intravenous infusion until disease progression is detected. Based on a population pharmacokinetic analysis of patients who received 1–20 mg/kg of bevacizumab once every 1–3 weeks, the estimated half-life was approximately 20 days, and the predicted time to reach steady state was 100 days. The maximum and minimum steady-state serum concentrations at 2.5 mg/kg/week dose were 226 and 88 μg/mL, respectively. Clearance of bevacizumab is low, and varies with body weight, gender and tumor burden. In patients with colorectal cancer receiving bevacizumab 5–10 mg/kg in combination with fluorouracil and leucovorin, mean total clearance was 2.79 ml/kg/day. In clinical studies involving the administration of bevacizumab (5 mg/kg every 2 weeks) or placebo in addition to bolus-IFL (irinotecan 125 mg/m² i.v., 5-fluorouracil 500 mg/ m² i.v., and leucovorin 20 mg/m² i.v. administered once weekly for four weeks every six weeks), the median overall survival was significantly increased from 15.6 months in the bolus IFL + placebo arm to 20.3 months in the bolus IFL + bevacizumab arm. Similar increases were also seen in progression-free survival (6.4 versus 10.6 months), overall response rate (35% versus 45%), and duration of response (7.1 months versus 10.4 months). The most common adverse events in these trials were hypertension, diarrhea and leucopenia. Other clinically significant adverse events reported occasionally were gastrointestinal perforations, thromboembolic events, bleeding and proteinuria. Because wound healing may be impaired by inhibition of VEGF, bevacizumab therapy is not recommended until 28 days after primary surgery.

 

 

      All Key Manufacturers and Suppliers of Baoji Guokang have routine inspections to ensure they are in compliance with the standards set in place during the original Supplier Assessment Inspection.

 

   Production Inspection Process:

Our Group service includes regular and thorough inspections throughout the manufacturing process, eliminating the need to employ additional quality control inspectors.

- Raw material before any production begins

- Pre-production samples to ensure specifications are being met

- In-process to confirm that standards are maintained

- Pre-shipping to ensure that the product arrives to the customer exactly as expected and is packaged

correctly to prevent any damage in transit.

 

   

     We can help operating split shipments, meeting the factory minimum quantity but ship them in 2 or 3 shipments with required gaps among. This allows you to move stock through your business without taking up space and capital.

We will arrange the subsequent shipments from our factory to your warehouse.

We can consolidate your small orders from multiple factories, delivering all at the same time to you or your customers,using the most cost-effective route available. At the time of order placement, we will offer details to you about the volume of each component part and what size container will be used.

 

    We can offer the complete package from concept to delivery; arranging everything up until products arrive at your own door or distribution hub.

   Delivery can be offered.

    - Utilizing your own freight-forwarder

    - FOB to a port in China

    - CIF to a port near you

   Whether you have your own freight-forwarder or you would like to organize shipment; whether you require delivery FOB in China or CIF to a port near you, we are glad to quote and supply whichever way you choose. Please feel free to discuss all options with us.

 

 

 

1.Client is first.We are trying to bring maximum profit to our clients and we only share small.

2.Credibility is the most important.

3.Quality control is our life.

4.Great sense of responsibility.

We will be responsible for not only our products, our clients, our suppliers, also the society.